东亚药业(605177) - 2025 Q2 - 季度业绩预告

Key Performance Forecast Data for the Current Period The company forecasts a net loss for H1 2025, with attributable net profit between -28 million and -35 million RMB and non-recurring adjusted net profit between -33 million and -40 million RMB 2025 Half-Year Performance Forecast | Indicator | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | -28 million to -35 million | | Net Profit Attributable to Shareholders After Non-Recurring Items | -33 million to -40 million | - These performance forecast data are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[5] Prior Period Operating Performance The company reported a profit in H1 2024, with attributable net profit of 32.473 million RMB and non-recurring adjusted net profit of 26.9332 million RMB, contrasting the H1 2025 forecast loss 2024 Half-Year Performance (Prior Period) | Indicator | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | 32.473 million | | Net Profit Attributable to Shareholders After Non-Recurring Items | 26.9332 million | | Earnings Per Share | 0.29 | Analysis of Current Period Forecast Loss The company's shift to a loss is primarily due to a 30 million RMB decrease in gross profit from reduced market demand and an estimated 30 million RMB inventory impairment provision Revenue Side Impact Reduced terminal demand for some products, influenced by global economic slowdown and competition, led to a year-on-year decrease of approximately 30 million RMB in gross profit - Due to global economic slowdown, industry policies, intensified competition, supply chain dynamics, and inventory pressure, some of the company's products face reduced demand[8] - These factors resulted in a year-on-year decrease of approximately 30 million RMB in the company's gross profit for the current reporting period[8] Asset Side Impact Based on prudence, the company plans to accrue approximately 30 million RMB in inventory impairment provisions for this period, as the net realizable value of some inventory is below cost - The company intends to accrue impairment provisions for assets that may show signs of impairment, primarily inventory[8] - An estimated 30 million RMB in inventory impairment provisions is planned for the current reporting period[8] Company Strategy and Countermeasures Despite short-term challenges, the company achieved a major strategic breakthrough with its first preparation approval, advancing its 'API-formulation integration' strategy, and is implementing cost control and organizational reforms - The company obtained its first preparation approval, marking a significant breakthrough in its 'API-formulation integration' development strategy[8] - The company is actively maintaining market share for its leading products, enriching its product pipeline, and fully advancing the implementation of its preparation business[9] - Management is implementing cost control and organizational reforms to improve operational quality and enhance product competitiveness[9] Risk Warning The company confirms no major uncertainties affecting the accuracy of this performance forecast, emphasizing that the disclosed financial data are preliminary and unaudited - The financial data contained in this announcement are preliminary calculations by the company's finance department based on prudence, and have not been audited by a certified public accountant[10] Other Explanatory Notes The company reiterates that the forecast data are preliminary, and final accurate financial figures will be based on the officially disclosed 2025 half-year report, advising investors to be aware of investment risks - The final accurate financial data will be subject to the company's officially disclosed 2025 half-year report, reminding investors to be aware of investment risks[11]